As Teva Pharmaceutical Industries LTD (TEVA) Market Valuation Declined, Dreman Value Management Increased Its Position; Halliburton (HAL) Stake Held by Lee Danner & Bass Inc

January 6, 2018 - By Nellie Frank

David Dreman increased its stake in Teva Pharmaceutical Industries Ltd. (TEVA) by 168.75% based on its latest 2017Q3 regulatory filing with the SEC. Dreman Value Management Llc bought 26,402 shares as the company’s stock declined 15.11% while stock markets rallied. The hedge fund run by David Dreman held 42,048 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $740,000, up from 15,646 at the end of the previous reported quarter. Dreman Value Management Llc who had been investing in Teva Pharmaceutical Industries Ltd. for a number of months, seems to be bullish on the $19.53 billion market cap company. The stock decreased 1.84% or $0.36 during the last trading session, reaching $19.22. About 13.27M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since January 6, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

Lee Danner & Bass Inc increased its stake in Halliburton Inc. (HAL) by 9.07% based on its latest 2017Q3 regulatory filing with the SEC. Lee Danner & Bass Inc bought 15,880 shares as the company’s stock declined 11.04% while stock markets rallied. The institutional investor held 190,879 shares of the oilfield services and equipment company at the end of 2017Q3, valued at $8.79M, up from 174,999 at the end of the previous reported quarter. Lee Danner & Bass Inc who had been investing in Halliburton Inc. for a number of months, seems to be bullish on the $45.22 billion market cap company. The stock increased 0.37% or $0.19 during the last trading session, reaching $51.82. About 8.62M shares traded or 6.27% up from the average. Halliburton Company (NYSE:HAL) has risen 19.03% since January 6, 2017 and is uptrending. It has outperformed by 2.33% the S&P500.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.09, from 0.94 in 2017Q2. It worsened, as 84 investors sold HAL shares while 297 reduced holdings. 71 funds opened positions while 254 raised stakes. 679.57 million shares or 0.21% less from 681.00 million shares in 2017Q2 were reported. Benjamin F Edwards invested in 1,937 shares. Fruth invested in 8,733 shares. Steinberg Global Asset Management holds 0.15% or 22,801 shares in its portfolio. Barrington Strategic Wealth Gru Limited Com has invested 0.12% in Halliburton Company (NYSE:HAL). Central National Bank & Trust has 0.02% invested in Halliburton Company (NYSE:HAL). Ftb Advisors has invested 0.01% in Halliburton Company (NYSE:HAL). Moreover, Sit Inv Assocs has 0% invested in Halliburton Company (NYSE:HAL). State Of Alaska Department Of Revenue invested 0.03% in Halliburton Company (NYSE:HAL). Eagle Asset Mgmt holds 722,928 shares. Johnson Investment Counsel has invested 0.01% in Halliburton Company (NYSE:HAL). Bank, Michigan-based fund reported 38,662 shares. Tower Bridge Advsrs, Pennsylvania-based fund reported 107,718 shares. Segall Bryant Hamill Ltd stated it has 348,275 shares or 0.37% of all its holdings. Assetmark has 1,990 shares. Moreover, Glenmede Tru Company Na has 0.19% invested in Halliburton Company (NYSE:HAL) for 919,794 shares.

Since September 5, 2017, it had 0 insider buys, and 1 insider sale for $1.71 million activity.

Among 39 analysts covering Halliburton Company (NYSE:HAL), 35 have Buy rating, 0 Sell and 4 Hold. Therefore 90% are positive. Halliburton Company had 135 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Thursday, October 20 with “Market Perform”. Bernstein initiated Halliburton Company (NYSE:HAL) on Friday, December 2 with “Outperform” rating. On Thursday, July 20 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm earned “Buy” rating on Thursday, July 21 by Deutsche Bank. The firm has “Buy” rating by Piper Jaffray given on Thursday, December 14. Citigroup maintained the stock with “Buy” rating in Wednesday, July 13 report. The firm has “Buy” rating by Goldman Sachs given on Monday, May 9. Howard Weil maintained it with “Sector Perform” rating and $57 target in Thursday, October 20 report. The rating was maintained by Barclays Capital with “Overweight” on Thursday, October 20. As per Wednesday, January 13, the company rating was upgraded by Seaport Global.

Lee Danner & Bass Inc, which manages about $1.12 billion and $929.08M US Long portfolio, decreased its stake in Accenture Ltd (NYSE:ACN) by 3,347 shares to 179,978 shares, valued at $24.31 million in 2017Q3, according to the filing. It also reduced its holding in Loews Corp. (NYSE:L) by 9,156 shares in the quarter, leaving it with 378,759 shares, and cut its stake in Cars.Com Inc..

Among 33 analysts covering Teva Pharma (NYSE:TEVA), 8 have Buy rating, 7 Sell and 18 Hold. Therefore 24% are positive. Teva Pharma had 125 analyst reports since July 21, 2015 according to SRatingsIntel. As per Wednesday, September 6, the company rating was maintained by JMP Securities. Barclays Capital maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Friday, October 20 with “Equal-Weight” rating. On Thursday, October 26 the stock rating was maintained by Mizuho with “Hold”. Leerink Swann maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Tuesday, July 21. Leerink Swann has “Outperform” rating and $74 target. On Wednesday, November 16 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. The stock has “Neutral” rating by Mizuho on Friday, November 17. The rating was downgraded by Deutsche Bank to “Hold” on Friday, November 3. Jefferies maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Tuesday, July 25. Jefferies has “Hold” rating and $3300 target. On Monday, January 9 the stock rating was downgraded by Wells Fargo to “Market Perform”. The firm earned “Reduce” rating on Tuesday, November 7 by HSBC.